Equity Research In Vitro & In Vivo Diagnostic Substances

Should You Buy Lantheus Holdings, Inc. Stock in 2026?

By CirclFi Research Team · · 13/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Lantheus Holdings, Inc. (LNTH) stands out as one of the highest-quality businesses in our coverage universe, earning a Quality of Company score of 10.0/10. At a current price of $104.40, the core investment question is whether the stock offers a compelling entry point relative to its estimated intrinsic value.

The short answer: 6 of 13 CirclFi valuation models project upside for Lantheus Holdings, Inc. (LNTH) at $104.40 — the model consensus leans bearish, with a Quality Score of 10.0/10 and Value-Trap risk of 12/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 7 of 13 models suggest overvaluation — majority bearish
  • Quality Score: 10.0/10 — Excellent — top-tier fundamentals
  • Value Trap Risk: 12/100 — Minimal — healthy fundamentals
  • Fair Value Range: $6.38 – $215.93 (3286% spread)

Bullish Models

6 / 13

Bearish Models

7 / 13

Quality Score

10.0 /10

Excellent — top-tier fundamentals

Value Trap Risk

12 /100
Minimal

Minimal — healthy fundamentals

Model Consensus

13 /13
Active Models

Avg. confidence: 46%

Investment Thesis

The Bull Case

Target: $215.93 (+106.8% upside)

  • According to the CirclFi Quality of Company (QOC) framework, Lantheus Holdings, Inc.'s score of 10.0/10 reflects durable competitive advantages that should sustain earnings power through market cycles.
  • According to the CirclFi Deep Alpha Valuation Engine, the RCMH-DCF model targets a fair value of $215.93 (+106.8%), anchoring the bull case with a methodology that provides a differentiated analytical lens.

The Bear Case

Target: $6.38 (-93.9%)

  • According to the CirclFi Deep Alpha Valuation Engine, the Dynamic NAV model sees the stock as overvalued with a fair value of $6.38 (-93.9%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +200.7% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology.

Peer Benchmarking

IDXX IDEXX Laboratories,
10.0
NEOG Neogen Corporation
7.6
ICCC ImmuCell Corporation
7.2
QDEL QuidelOrtho Corporat
6.8
NTLA Intellia Therapeutic
6.2

Valuation Divergence

Spread

3286%

Fair Value Range

$6.38 – $215.93

A 3286% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

RCMH-DCF

$215.93 (+106.8%)

Most Bearish

Dynamic NAV

$6.38 (-93.9%)

Key Risk Factors

Model Disagreement

3286% spread signals high variance in projections.

Bearish Consensus

7/13 models suggest overvaluation.

Macro/Sector Risk

In Vitro & In Vivo Diagnostic Substances headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View LNTH Data Page →

The Bottom Line

Lantheus Holdings, Inc. at $104.40 is a genuine coin-flip in our framework. The 5–7 bull-bear split across 13 models, +200.7% model spread, and composite fair value of $101.43 (-2.8% avg.) argue for a watchlist position rather than a high-conviction bet. Quality at 10.0/10 adds some comfort to the mix.

These are quantitative model outputs, not investment recommendations. Lantheus Holdings, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy LNTH stock right now?

Based on CirclFi's multi-model analysis, 6 of 13 models see upside for LNTH at $104.40. The models are divided, which means the investment case depends heavily on your assumptions about Lantheus Holdings, Inc.'s future. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Lantheus Holdings, Inc.?

Key risks include: wide model disagreement (3286% spread), signaling high uncertainty; general market and sector-specific risks affecting In Vitro & In Vivo Diagnostic Substances companies. Always diversify and consult a financial advisor.

How does LNTH compare to its competitors?

Among In Vitro & In Vivo Diagnostic Substances peers, LNTH holds a Quality Score of 10.0/10. Comparable companies include IDXX (QOC 10.0), NEOG (QOC 7.6), ICCC (QOC 7.2). The relative ranking helps investors identify whether LNTH offers better fundamental quality than alternatives in the same sector.

Is LNTH a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. LNTH's Quality Score of 10.0/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.

What price should I buy LNTH at?

CirclFi does not provide target buy prices or price alerts. However, our 13 active models produce fair value estimates ranging from $6.38 to $215.93. At $104.40, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for LNTH.

View LNTH Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →